Literature DB >> 33367854

Glucocorticoid-free treatment of severe ANCA-associated vasculitis.

Tariq E Farrah1,2, Maria Prendecki3,4, Robert W Hunter1,2, Rashmi Lahiri2, Thomas D Cairns4, Charles D Pusey3,4, Stephen P McAdoo3,4, Neeraj Dhaun1,2.   

Abstract

Entities:  

Year:  2021        PMID: 33367854      PMCID: PMC7611118          DOI: 10.1093/ndt/gfaa310

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  12 in total

1.  A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Ruth J Pepper; Stephen P McAdoo; Sarah M Moran; Dearbhla Kelly; Jennifer Scott; Sally Hamour; Aine Burns; Megan Griffith; Jack Galliford; Jeremy B Levy; Thomas D Cairns; Seerapani Gopaluni; Rachel B Jones; David Jayne; Mark A Little; Charles D Pusey; Alan D Salama
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

2.  Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Authors:  Michael Walsh; Peter A Merkel; Chen-Au Peh; Wladimir M Szpirt; Xavier Puéchal; Shouichi Fujimoto; Carmel M Hawley; Nader Khalidi; Oliver Floßmann; Ron Wald; Louis P Girard; Adeera Levin; Gina Gregorini; Lorraine Harper; William F Clark; Christian Pagnoux; Ulrich Specks; Lucy Smyth; Vladimir Tesar; Toshiko Ito-Ihara; Janak Rashme de Zoysa; Wojciech Szczeklik; Luis Felipe Flores-Suárez; Simon Carette; Loïc Guillevin; Charles D Pusey; Alina L Casian; Biljana Brezina; Andrea Mazzetti; Carol A McAlear; Elizabeth Broadhurst; Donna Reidlinger; Samir Mehta; Natalie Ives; David R W Jayne
Journal:  N Engl J Med       Date:  2020-02-13       Impact factor: 91.245

3.  Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Authors:  Rachel B Jones; Thomas F Hiemstra; Jose Ballarin; Daniel Engelbert Blockmans; Paul Brogan; Annette Bruchfeld; Maria C Cid; Karen Dahlsveen; Janak de Zoysa; Georgína Espigol-Frigolé; Peter Lanyon; Chen Au Peh; Vladimir Tesar; Augusto Vaglio; Michael Walsh; Dorothy Walsh; Giles Walters; Lorraine Harper; David Jayne
Journal:  Ann Rheum Dis       Date:  2019-01-05       Impact factor: 19.103

4.  Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis.

Authors:  Mark A Little; Peter Nightingale; C A Verburgh; Thomas Hauser; Kirsten De Groot; Caroline Savage; David Jayne; Lorraine Harper
Journal:  Ann Rheum Dis       Date:  2009-07-01       Impact factor: 19.103

5.  Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

Authors:  Kirsten de Groot; Lorraine Harper; David R W Jayne; Luis Felipe Flores Suarez; Gina Gregorini; Wolfgang L Gross; Rashid Luqmani; Charles D Pusey; Niels Rasmussen; Renato A Sinico; Vladimir Tesar; Philippe Vanhille; Kerstin Westman; Caroline O S Savage
Journal:  Ann Intern Med       Date:  2009-05-19       Impact factor: 25.391

6.  Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.

Authors:  Joanna Robson; Helen Doll; Ravi Suppiah; Oliver Flossmann; Lorraine Harper; Peter Höglund; David Jayne; Alfred Mahr; Kerstin Westman; Raashid Luqmani
Journal:  Rheumatology (Oxford)       Date:  2014-09-08       Impact factor: 7.580

7.  Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study.

Authors:  Dimitrios Chanouzas; Julie Anne G McGregor; Peter Nightingale; Alan D Salama; Wladimir M Szpirt; Neil Basu; Matthew David Morgan; Caroline J Poulton; Juliana Bordignon Draibe; Elizabeth Krarup; Paula Dospinescu; Jessica Anne Dale; William Franklin Pendergraft; Keegan Lee; Martin Egfjord; Susan L Hogan; Lorraine Harper
Journal:  BMC Nephrol       Date:  2019-02-18       Impact factor: 2.388

8.  Long-term outcomes in elderly patients with ANCA-associated vasculitis.

Authors:  Dominic McGovern; Sam P Williams; Katrina Parsons; Tariq E Farrah; Peter J Gallacher; Eve Miller-Hodges; David C Kluth; Robert W Hunter; Neeraj Dhaun
Journal:  Rheumatology (Oxford)       Date:  2020-05-01       Impact factor: 7.580

9.  Characterizing infection in anti-neutrophil cytoplasmic antibody-associated vasculitis: results from a longitudinal, matched-cohort data linkage study.

Authors:  Shifa H Sarica; Neeraj Dhaun; Jan Sznajd; John Harvie; John McLaren; Lucy McGeoch; Vinod Kumar; Nicole Amft; Lars Erwig; Angharad Marks; Corri Black; Neil Basu
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

10.  Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study.

Authors:  Daisuke Waki; Keisuke Nishimura; Hironobu Tokumasu; Keiichiro Kadoba; Hiroki Mukoyama; Rintaro Saito; Hiroyuki Murabe; Toshihiko Yokota
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more
  3 in total

1.  Strawberry carina as a presentation of anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Gavin B Chapman; Andrew E Leitch; Rashmi Lahiri; Peter Reid; Neeraj Dhaun
Journal:  Rheumatology (Oxford)       Date:  2022-03-02       Impact factor: 7.580

Review 2.  The Impact of High Dose Glucocorticoids on Bone Health and Fracture Risk in Systemic Vasculitides.

Authors:  Christopher David Box; Owen Cronin; Barbara Hauser
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-16       Impact factor: 5.555

3.  Utility of interval kidney biopsy in ANCA-associated vasculitis.

Authors:  Gavin B Chapman; Tariq E Farrah; Fiona A Chapman; Dan Pugh; Christopher O C Bellamy; Rashmi Lahiri; Eve Miller-Hodges; David C Kluth; Robert W Hunter; Neeraj Dhaun
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.